Skip to Content

Insulin Detemir (Levemir), a New Long-Acting Insulin

Insulin detemir (Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in position B30 and the addition of a 14-carbon fatty acid chain at position B29. Insulin glargine (Lantus), the first long-acting insulin analog, has been available since 2001 and is usually given once daily.1 NPH insulin is an intermediate-acting basal insulin given twice daily. Basal insulins are usually combined with prandial doses of a rapid-acting insulin....
Cannot Access - We are sorry, but you cannot access the requested article.
login now
login now
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Insulin Detemir (Levemir), a New Long-Acting Insulin
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1238
Article Code: 1238b
Date: July 3, 2006
Volume: 48
Pages: 54-55

 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.
 Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.